Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Radiology

Breast Fibroadenoma on Ultrasound: Is Biopsy Needed?

At a Glance

A breast fibroadenoma with classic benign ultrasound features may be monitored instead of biopsied, often with short-interval follow-up. A core needle biopsy is usually recommended for BI-RADS 4 or 5 findings, substantial growth, large or suspicious masses, or higher cancer risk.

Finding a breast lump is frightening, and it is natural to want immediate answers. However, a breast mass that looks like a classic fibroadenoma on ultrasound does not automatically require a core needle biopsy [1]. If the lesion has classic benign (non-cancerous) features, your care team may recommend monitoring it with follow-up ultrasounds. This “watch and wait” approach is an active, guideline-supported plan, not simply doing nothing [2]. However, a tissue biopsy is usually recommended if the mass is large, growing rapidly, shows suspicious features on imaging, or if your age and medical history increase your baseline risk for breast cancer [3][4][5].

The BI-RADS System: How Doctors Decide

Radiologists use a system called BI-RADS (Breast Imaging Reporting and Data System) to categorize ultrasound findings. The BI-RADS category is a key factor in deciding the next steps.

BI-RADS Category What It Means Typical Recommendation
BI-RADS 2 (Benign) The finding is definitively benign (0% chance of cancer). Return to age-appropriate clinical follow-up or screening.
BI-RADS 3 (Probably Benign) The mass has classic benign features (e.g., oval, smooth margins). Risk of cancer is less than 2%. Short-interval monitoring with ultrasound.
BI-RADS 4 (Suspicious) The mass has suspicious features. Divided into 4A (low suspicion), 4B (moderate), and 4C (high). Core needle biopsy is usually recommended.
BI-RADS 5 (Highly Suggestive of Malignancy) The mass has classic malignant features (≥95% chance of cancer). Core needle biopsy is strongly recommended.

Monitoring vs. Biopsy: Understanding the Trade-Offs

When deciding between monitoring a BI-RADS 3 lesion and having a biopsy, it helps to understand the trade-offs of each approach:

Choosing to Monitor

For a BI-RADS 3 mass, the standard approach is short-interval monitoring. A common schedule involves follow-up ultrasounds at 6, 12, and 24 months, though protocols can vary based on your age and clinic [2].

  • Benefits: You avoid a medical procedure and its associated risks. For adolescents and young women, observation is especially common [6].
  • Downsides: It requires scheduled follow-up visits and living with a very small amount of residual uncertainty about the exact nature of the mass.

Choosing a Core Needle Biopsy

A core needle biopsy uses a hollow needle to remove small tissue samples from the mass.

  • Benefits: It provides a definitive tissue diagnosis and can relieve the anxiety of uncertainty.
  • Downsides: It is a medical procedure that uses local anesthetic and carries small risks of bruising, pain, bleeding, or infection. A tiny metal marker clip is usually left in the breast. Occasionally, the sample might be inconclusive, requiring a repeat biopsy.

Your doctor will usually recommend a biopsy if the mass is categorized as BI-RADS 4 or if your clinical picture warrants closer investigation [4]. Key factors include:

  • Suspicious imaging features: If the ultrasound shows an irregular shape, spiculated (spiky) margins, or a nonparallel orientation (meaning the mass is “taller than wide”), a biopsy is usually recommended to rule out cancer [4][7].
  • Changes during monitoring: If a lesion being monitored grows substantially or develops new suspicious features, it may be upgraded to BI-RADS 4, prompting a biopsy [4][2].
  • Size and rapid growth: A rapidly growing mass, or a very large mass (for example, larger than 3 to 4 centimeters), raises concern for other conditions and may lead your doctor to recommend tissue sampling or surgical consultation [3][8].
  • Age and risk history: Finding a new palpable mass in a woman over age 40 carries a higher index of suspicion, and evaluation typically involves a mammogram or 3D mammogram (tomosynthesis) in addition to an ultrasound [5][3]. A strong personal or family history of breast cancer also lowers the threshold for recommending a biopsy [5][9].
  • Diagnostic vs. Elective Removal: If a mass is causing persistent pain, or if you strongly prefer it removed for peace of mind, elective surgical removal may be discussed. However, pain alone does not automatically mean cancer or require a biopsy [3][10].

Note: You should seek prompt clinical review if you notice rapid enlargement, skin dimpling, nipple retraction, bloody discharge, or a new lump under your arm.

Sometimes a doctor will recommend a biopsy even if they strongly suspect a fibroadenoma. This is usually to address uncommon situations where imaging isn’t enough:

  1. Rare Mimics: Rarely, certain types of breast cancer (like triple-negative cancer) can look like smooth, benign masses on an ultrasound [11].
  2. Phyllodes Tumors: A phyllodes tumor is an uncommon fibroepithelial lesion that looks almost identical to a fibroadenoma on imaging but can grow aggressively [3]. A core biopsy helps distinguish between the two, though sometimes surgical removal is still needed for a definitive answer [12][13].

What Happens After a Biopsy?

After a biopsy, your care team will perform a crucial quality-assurance check called radiologic-pathologic concordance. This means they verify that the tissue diagnosis adequately explains the ultrasound appearance [14]. Because a core biopsy only samples a small part of the tumor, it is important that the pieces match the whole picture.

  • Concordant Fibroadenoma: If the biopsy confirms a fibroadenoma with no atypical (abnormal-looking) cells, and this matches the ultrasound, you generally do not need further short-term imaging. You can return to the clinical follow-up or screening plan appropriate for your age and risk [10][15].
  • Discordant or Indeterminate Results: If the tissue sample does not explain the ultrasound findings, or if atypia or a possible phyllodes tumor is found, the results are discordant. Your doctor will likely recommend a repeat biopsy or surgical excision to be absolutely certain [10][14].

Common questions in this guide

Does every breast fibroadenoma seen on ultrasound need a core needle biopsy?
No. A mass with classic benign features may be monitored with follow-up ultrasound, especially when it is categorized as BI-RADS 2 or BI-RADS 3. Biopsy is more likely when the mass looks suspicious, grows, is large, or occurs with higher breast-cancer risk.
What does BI-RADS 3 mean when a breast mass looks like a fibroadenoma?
BI-RADS 3 means the mass is probably benign, with a risk of cancer below 2 percent. Doctors commonly recommend short-interval ultrasound follow-up, often at about 6, 12, and 24 months, although the schedule can vary.
When is a biopsy recommended for a breast mass that resembles a fibroadenoma?
A core needle biopsy is usually recommended for BI-RADS 4 or BI-RADS 5 findings, or when ultrasound shows features such as an irregular shape, spiky margins, or a mass that is taller than wide. Biopsy may also be advised if the mass grows substantially, enlarges rapidly, is very large, or occurs with important personal or family risk factors.
Can a phyllodes tumor look like a fibroadenoma on ultrasound?
Yes. A phyllodes tumor is uncommon and can resemble a fibroadenoma on imaging, but it may grow aggressively. A core needle biopsy can help distinguish them, although surgical removal is sometimes needed for a definitive diagnosis.
What happens after a biopsy confirms a fibroadenoma?
The care team checks whether the tissue result matches the ultrasound appearance, a process called radiologic-pathologic concordance. If the biopsy confirms a fibroadenoma without atypical cells and the results match the imaging, short-term imaging may not be needed; results that are unclear or do not match may require another biopsy or surgical excision.

Get notified when new evidence is published on breast fibroadenoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Understanding BI-RADS Category 3.

    Fazeli S, Stepenosky J, Guirguis MS, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(1)):e240169 doi:10.1148/rg.240169.

    PMID: 39636752
  2. 2

    Evaluation of Two-Year Follow-Up of Patients with BI-RADS 3 Breast Ultrasound Lesions in a Single Private Ultrasound Study.

    Adibi A, Asadollahi Z

    Advanced biomedical research 2023; (12()):236 doi:10.4103/abr.abr_10_23.

    PMID: 38073756
  3. 3

    Which lesions with a radiological or core biopsy diagnosis of fibroadenoma should be excised?

    Lee A, James J, Whisker L, et al.

    Annals of the Royal College of Surgeons of England 2022; (104(5)):361-366 doi:10.1308/rcsann.2021.0208.

    PMID: 34939848
  4. 4

    Nonpalpable BI-RADS 4 breast lesions: sonographic findings and pathology correlation.

    Elverici E, Barça AN, Aktaş H, et al.

    Diagnostic and interventional radiology (Ankara, Turkey) 2015; (21(3)):189-94 doi:10.5152/dir.2014.14103.

    PMID: 25835079
  5. 5

    Modeling risk assessment for breast cancer in symptomatic women: a Saudi Arabian study.

    Ahmed AE, McClish DK, Alghamdi T, et al.

    Cancer management and research 2019; (11()):1125-1132 doi:10.2147/CMAR.S189883.

    PMID: 30787637
  6. 6

    Pediatric Breast Pathologies: 5-Year Experience and Proposal for a Risk-Based Management Algorithm.

    Sağ S, Sonmez Y, Gungormez EK, et al.

    Journal of pediatric and adolescent gynecology 2026; (39(4)):467-473 doi:10.1016/j.jpag.2026.01.287.

    PMID: 41638525
  7. 7

    Features of breast cancer initially assessed as probably benign on ultrasound: A retrospective study.

    Ryu HJ, Cha JH, Kim HH, et al.

    Medicine 2022; (101(31)):e29953 doi:10.1097/MD.0000000000029953.

    PMID: 35945803
  8. 8

    Core needle biopsy in fibroepithelial tumors: predicting factors for phyllodes tumors.

    Reis YN, Maesaka JY, Shimizu C, et al.

    Clinics (Sao Paulo, Brazil) 2021; (76()):e2806 doi:10.6061/clinics/2021/e2806.

    PMID: 33886790
  9. 9

    Management of breast complaints and high-risk lesions.

    Pleasant V

    Best practice & research. Clinical obstetrics & gynaecology 2022; (83()):46-59 doi:10.1016/j.bpobgyn.2022.03.017.

    PMID: 35570155
  10. 10

    American Society of Breast Surgeons and Society of Breast Imaging 2025 Guidelines for the Management of Benign Breast Fibroepithelial Lesions.

    Rosenberger LH, White RL, Tafra L, et al.

    JAMA surgery 2025; (160(12)):1378-1385 doi:10.1001/jamasurg.2025.4392.

    PMID: 41123921
  11. 11

    Radiomics of US texture features in differential diagnosis between triple-negative breast cancer and fibroadenoma.

    Lee SE, Han K, Kwak JY, et al.

    Scientific reports 2018; (8(1)):13546 doi:10.1038/s41598-018-31906-4.

    PMID: 30202040
  12. 12

    Diagnosis and management of phyllodes tumours for the surgeon: An algorithm.

    Ofri A, Stuart KE, Chan B, et al.

    The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2022; (20(6)):e355-e365 doi:10.1016/j.surge.2022.01.004.

    PMID: 35148937
  13. 13

    Fibroepithelial Lesion Spectrum: A Case Report Documenting a Possible Transformation to a Malignant Phyllodes Tumor.

    Felsen A, Maldjian C, Hodges L, et al.

    Cureus 2023; (15(4)):e38252 doi:10.7759/cureus.38252.

    PMID: 37252609
  14. 14

    Image-guided breast biopsy and localisation: recommendations for information to women and referring physicians by the European Society of Breast Imaging.

    Bick U, Trimboli RM, Athanasiou A, et al.

    Insights into imaging 2020; (11(1)):12 doi:10.1186/s13244-019-0803-x.

    PMID: 32025985
  15. 15

    Results of Short-Term Follow-Up in BI-RADS 3 and 4a Breast Lesions with a Histological Diagnosis of Fibroadenoma at Percutaneous Needle Biopsy.

    Clauser P, Bazzocchi M, Marcon M, et al.

    Breast care (Basel, Switzerland) 2017; (12(4)):238-242 doi:10.1159/000477536.

    PMID: 29070987

This page is for informational purposes only and does not constitute medical advice or diagnose your breast lump. Discuss your BI-RADS result and biopsy options with your healthcare team.